一种识别髓系和淋巴细胞上独特抗原的新型单克隆抗体6G7的特性分析。

Characterization of a new monoclonal antibody 6G7 that recognizes a unique antigen on myeloid and lymphoid cells.

作者信息

Chen J, Zhou J H, Ball E D

机构信息

Department of Medicine and Cancer Center, University of California, San Diego School of Medicine, La Jolla, CA 92093-0960, USA.

出版信息

J Hematother Stem Cell Res. 2001 Apr;10(2):237-46. doi: 10.1089/15258160151134926.

DOI:10.1089/15258160151134926

PMID:11359671

Abstract

We generated a monoclonal antibody (mAb) 6G7, which recognizes a 220-kD antigen on selected subpopulations of normal myeloid and lymphoid cells and their malignant counterparts. 6G7 reacts with 90-95% of peripheral blood B cells, 70-80% of CD8(+) cells, 30-35% of CD4(+) cells, 20-40% of monocytes, and 20-40% of CD34(+) cells from bone marrow. 6G7 reacts with leukemic blasts in acute myeloid leukemia (14/16), adult acute lymphoblastic leukemia (ALL) (5/5), pediatric ALL (5/9), chronic lymphocytic leukemia (8/8), follicular lymphoma (7/7), and Burkitt's lymphoma (1/1). Long-term bone marrow culture of 6G7(+/-) cells showed the majority of clonogenic hematopoietic cells were in mAb 6G7 subpopulation. An immunotoxin of 6G7 and ricin A chain was cytotoxic to 6G7(+) leukemia cell lines. mAb 6G7 has potential clinical applications for targeted immunotherapy of both leukemia and lymphoma.

摘要

我们制备了一种单克隆抗体（mAb）6G7，它能识别正常髓系和淋巴系细胞及其恶性对应细胞的特定亚群上的一种220-kD抗原。6G7与90-95%的外周血B细胞、70-80%的CD8(+)细胞、30-35%的CD4(+)细胞、20-40%的单核细胞以及20-40%的来自骨髓的CD34(+)细胞发生反应。6G7与急性髓系白血病（14/16）、成人急性淋巴细胞白血病（ALL）（5/5）、儿童ALL（5/9）、慢性淋巴细胞白血病（8/8）、滤泡性淋巴瘤（7/7）和伯基特淋巴瘤（1/1）中的白血病原始细胞发生反应。6G7(+/-)细胞的长期骨髓培养显示，大多数克隆形成造血细胞位于mAb 6G7亚群中。6G7与蓖麻毒素A链的免疫毒素对6G7(+)白血病细胞系具有细胞毒性。mAb 6G7在白血病和淋巴瘤的靶向免疫治疗中具有潜在的临床应用价值。